Literature DB >> 35802301

Improvement of vanishing bile duct syndrome with hyperlipidemia.

Ryo Yamauchi1, Kazuhide Takata2, Atsushi Fukunaga2, Takashi Tanaka2, Keiji Yokoyama2, Satoshi Shakado2, Kazuki Nabeshima3, Kengo Yoshimitsu4, Fumihito Hirai2.   

Abstract

A 75-year-old man was admitted to our hospital with acute onset of marked jaundice, elevated liver enzymes, and hyperlipidemia. He had been taking clopidogrel and pemafibrate for 3 months. He tested negative for autoantibodies and hepatitis-causing viruses. Gadoxetate-enhanced magnetic resonance imaging showed diffusely hypointense liver parenchyma in the hepatobiliary phase, with no appreciable excretion of gadoxetate into the biliary system. Histological examination of a liver specimen revealed disappearance of the bile ducts in the portal area and decreased expression of organic transporting polypeptide 1B3 on immunostaining. The patient was diagnosed with drug-induced vanishing bile duct syndrome and treated with ursodeoxycholic acid. The signs of liver dysfunction shown on blood chemistry tests improved spontaneously. After the acute hepatitis and lipid abnormalities had improved, repeat liver biopsy and gadoxetate-enhanced magnetic resonance imaging revealed improvement of the vanishing bile duct syndrome and recovery of the expression of organic transporting polypeptide 1B3. The reduction of OATP1B3 expression might be involved in the development of vanishing bile duct syndrome.
© 2022. Japanese Society of Gastroenterology.

Entities:  

Keywords:  Drug-induced liver injury; Hyperlipidemia; Jaundice; Vanishing bile duct syndrome

Mesh:

Year:  2022        PMID: 35802301     DOI: 10.1007/s12328-022-01650-4

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  2 in total

1.  Hepatobiliary and Pancreatic: Sertraline-induced vanishing bile duct syndrome treated with plasmapheresis.

Authors:  J Tejedor-Tejada; F García-Pajares; B Madrigal Rubiales
Journal:  J Gastroenterol Hepatol       Date:  2018-12-09       Impact factor: 4.029

2.  Fenofibrate-induced acute cholestatic hepatitis.

Authors:  Chiu-Yung Ho; Tzong-Haur Kuo; Tseng-Shing Chen; Shyh-Haw Tsay; Full-Young Chang; Shou-Dong Lee
Journal:  J Chin Med Assoc       Date:  2004-05       Impact factor: 2.743

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.